

*Innovative, Clinically Proven*

# *Pain Management System*

© PNI Institute, 2013-2023. Unauthorized use and/or duplication of this material without express and written permission from Andrew D. Valencia, PA-C, Owner, is strictly prohibited. Excerpts and links may not be used without the explicit written preauthorization from Andrew D. Valencia, PA-C.

## *Tomorrow's Core Pain Treatment Technology Today*


Applied Translational Medicine

- Coupled Neuraxial Mesoscopic Desynchronization Electrostimulation Therapy (cNMDET)- **Non-Invasive, Out-Patient, "paradigm shift"**
- USPTO Patent #8,428,738 Awarded 23 April 2013
- Provides 'Preferred Clinical and Economic Outcomes'
- Affords 'Improved Quality of Life (QOL) Indices'
- Technology Readiness Level (TRL) 8
- Demonstrated 'Proof of Concept'
- **Therapeutic Multiplier, Multipotent** in Beneficial Effects, **Case-Based Reasoning, Reduces Opiate Dependency**

## *Mechanism(s)*

- **Functionally Reverses CNS and PNS Neuroplastic Changes** that Subserve the Clinical Event of 'Pain' and that contributes to the 'Chronification' (Flor '94) and the Exacerbation of Pain as with Central Sensitization
- Targets **Post Acute Pain, Neuropathic Pain** & various forms of 'Chronic Pain', **Sympathetically Mediated Pain** [Complex Regional Pain Syndromes (CRPS I & II, RSD, etc.), Thalamic Dysrhythmia Syndromes, Fibromyalgia, Migraine HAs, Trigeminal Neuralgias including TMJ Syndromes, Myofascial Pain Syndromes including Trigger Points, Barré-Liéou Syndrome, Radiculitis / Radicular Pain Syndrome, Brachial Plexitis (Parsonage Turner Syndrome, neurogenic, non-compressive), Carpal Tunnel Syndrome, Tarsal Tunnel Syndrome *and more ...*
- Targeted Research: Neuroinflammatory, Rheumatoidal & AutoImmune Processes (e.g. **MS, RA**, etc.), **Seizures, Phantom Limb Pain** *and more ...*

1990's- Actual



2012- Simulation



## *Market*


- Any Solo, Group or Institutional Practice with a Pain Population of **5% or More**
- Conservative Estimates from **\$88.7 Billion** (JAMA) to in Excess of **\$100 Billion** Annually

## *'Obamacare' - What Impact?*

- **Outcomes Exceed** Anticipated 'Comparative Effectiveness Research' Standards
- Designed to Economically **Thrive with Medicare & Medicaid Reimbursement Rates**
- Captures Trend for Increased Reimbursements for 'Primary Care' Level Services
- Projected **Accured Net Operating Income** of **\$363,249,308** Over a 7 Yr. Plan, With or Without 'Obamacare'

## *Business Opportunity*

- **New Mexico**- Phase I thru IV (3 Yrs.) 2 Demonstration / Training / Clinic Sites and **Licensee Recruitment**
- **US**- Phases V thru VII (3 Yrs.), 7 Demonstration / Training / Clinic Sites, 2 Data Redundancy / Research Sites
- **Investment of \$1.5 M, Exit at End of 5th Yr.**



## *The System Architecture That Makes A Difference*

- P<sup>3</sup>N (Provider to Provider to Patient Networking), Infinitely Scalable
- MPOC (Mobile Point of Care), Care Team Coherence, *and more*

## *Management Team*

- Andrew D. Valencia, PA-C, Inventor
- Recruiting:
  - Medical Director (Physiatrist / Neurologist) Pain Specialty with Greater than 10 Yrs. Experience
  - Ambulatory Healthcare Administrator, 10 Yrs. Experience
  - Mid-Levels (PAs, NPs), 10 Yrs. Experience

©Presented By:

**Andrew D. Valencia, PA-C**

**PNI Institute** [DEDICATED CORPORATION]

1335 Paseo Del Pueblo Sur, #159

Taos, NM 87571

(575) 751-4070

**advalencia@pniinstitute.org**

